Towards Personalized Cancer Medicine

迈向个性化癌症医学

• 批准号: 7805025
• 负责人: JOAN MASSAGUE
• 金额: $ 1.5万
• 依托单位: NEW YORK ACADEMY OF SCIENCES
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7805025
• 关键词: Academia; Academy; Address; Area; Award; Bioinformatics; Cancer Biology; Cancer Patient; Caring; Cellular biology; Clinical; Clinical Treatment; Clinical Trials; Collaborations; Data; Development; Diagnosis; Discipline; Disease; Doctor of Philosophy; Electronics; Elements; Epigenetic Process; Event; Family; Fees; Fostering; Friends; Future; Genetic; Genetic Programming; Genomics; Goals; Grant; Health; Industry; Institutes; Interdisciplinary Study; Interest Group; International; Knowledge; Life; Malignant Neoplasms; Medical Research; Medicine; Museums; National Cancer Institute; Nature; New York; Participant; Physicians; Predisposition; Prevention; Principal Investigator; Printing; Proteomics; Research; Research Personnel; Research Training; San Francisco; Science; Scientist; Translations; Travel; University Hospitals; Work; abstracting; anticancer research; base; cancer care; cancer imaging; cancer therapy; clinical care; drug development; experience; health care service organization; improved; lectures; meetings; member; mouse model; multidisciplinary; oncology; outcome forecast; posters; programs; response; success; symposium; therapy development; tumor; tumor molecular fingerprint

DESCRIPTION (provided by applicant): The New York Academy of Sciences is planning a landmark international program, "Towards Personalized Cancer Medicine", to explore the personalization of cancer predisposition, diagnosis, prognosis, treatment, and therapy development. The principal investigator for this grant is Dr. Joan Massagu?, Chair of the Cancer Biology and Genetics Program in the Sloan-Kettering Institute, New York. The program will include a 3-day live symposium (to be held in May 2010 in Barcelona) and the development of high-quality print and electronic enduring materials to disseminate the scientific information exchanged by the conference participants. It is very timely that the plethora of data emerging from the molecular signatures of cancers is shared across disciplines to identify the steps toward to the effective personalization (individualization) of cancer medicine. The main goals of this program are: 1) to foster dialogue among basic and clinical scientists working in areas of cancer research and oncology leading to a personalized treatment of malignant tumors; and 2) to generate comprehensive and cross-disciplinary approaches for the translation of personalized cancer research into individualized clinical treatments for cancer. We anticipate an advancement in cancer research and clinical therapy personalization to result from the discussions, enduring materials, and collaborations generated at this meeting. Cancer patients will benefit from discoveries and approaches resulting from this symposium, which is in perfect line with The National Cancer Institute's commitment to supporting research, training and health information relevant to the cause, diagnosis, prevention, and treatment of cancer, and to the care of cancer patients and their families. To achieve these goals, the conference will incorporate a combination of plenary lectures, a keynote address, and several elements to encourage networking and audience participation, and to highlight promising young scientists. The program will include a panel discussion, poster and short presentations selected from submitted abstracts, networking breaks, a conference reception, and the availability of travel awards. The conference will attract wide participation (250 attendees) among senior and young scientists, clinicians, and physicians working in the fields of genomics, bioinformatics, proteomics, genetics, epigenetics, cell biology, mouse models of cancer, imaging, drug development, and clinical trials, among others. In addition, we expect this group to include people from academia, industry, regulatory agencies, health care organizations, and other groups interested in the individualized targeting of cancer medicine.

描述（由申请人提供）：纽约科学院正在计划一项具有里程碑意义的国际计划，即“迈向个性化癌症医学”，以探索癌症易感性，诊断，预后，治疗和治疗开发的个性化。该赠款的主要研究人员是纽约斯隆 - 凯特林研究所的癌症生物学和遗传学计划主席Joan Massagu？该计划将包括为期3天的现场研讨会（将于2010年5月在巴塞罗那举行），以及开发高质量印刷品和电子持久材料，以传播会议参与者交换的科学信息。 非常及时的是，从癌症的分子特征中出现的大量数据在各学科中共享，以确定迈向癌症医学的有效个性化（个性化）的步骤。该计划的主要目标是：1）在癌症研究和肿瘤学领域工作的基础和临床科学家之间进行对话，从而导致对恶性肿瘤的个性化治疗； 2）生成全面和跨学科的方法，以将个性化癌症研究转化为个性化的癌症临床治疗。 我们预计癌症研究和临床疗法个性化的进步将是由于本次会议上产生的讨论，持久材料和合作而产生的。癌症患者将受益于该研讨会引起的发现和方法，该研讨会与国家癌症研究所致力于支持与癌症的原因，诊断，预防和治疗以及癌症患者及其家人有关的研究，培训和健康信息的承诺完全吻合。 为了实现这些目标，会议将结合全体讲座，主题演讲和几个要素，以鼓励网络和观众参与，并突出有希望的年轻科学家。该计划将包括小组讨论，海报和简短的演示文稿，从提交的摘要，网络休息，会议接待处以及旅行奖励的可用性中选择。该会议将吸引在基因组学，生物信息学，蛋白质组学，遗传学，表观遗传学，细胞生物学，癌症，成像，药物开发和临床试验等领域的高级和年轻科学家，临床医生和医生中吸引广泛的参与（250名与会者）。此外，我们预计该小组将包括来自学术界，工业，监管机构，医疗保健组织以及对癌症医学个性化靶向的其他群体的人。